AndroScience Corporation Enters Clinical Stage
Prior to this clinical stage, AndroScience won the Third Place Award (out of >900 posters) for its presentation entitled "Androgen Receptor Degradation (ARD) Enhancer: A Potential Application for Topical Treatment of Acne Vulgaris" at the Annual Meeting of American Academy of Dermatology in March of 2006; and in July 2006, AndroScience was awarded a Phase II SBIR grant ($800,000) from the NIH to develop ASC-J9 for acne treatment.
AndroScience also has drug candidates in preclinical testing for the treatment of alopecia, prostate cancer, benign prostate hyperplasia (BPH) and other androgen related disorders. AndroScience intends to build up corporate value by developing its proprietary compounds through preclinical and clinical development to registration and commercialization.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Smith, James. "AndroScience Corporation Enters Clinical Stage." Medical News Today. MediLexicon, Intl., 14 Feb. 2007. Web.
25 Jun. 2017. <http://www.medicalnewstoday.com/releases/62988.php>
Smith, J. (2007, February 14). "AndroScience Corporation Enters Clinical Stage." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.